An MIT pro­fes­sor's rare dis­ease quest rip­ples through­out biotech

Illustration: Henry Smith for Endpoints News

A decade ago, An­drew Lo des­per­ate­ly sought out a ther­a­py for his moth­er’s lung can­cer that had de­vel­oped re­sis­tance to ex­ist­ing drugs.

As part of the quest, he met with two biotech ex­ec­u­tives. Lo, a fi­nance pro­fes­sor at Mass­a­chu­setts In­sti­tute of Tech­nol­o­gy, ca­su­al­ly asked over lunch if fund­ing in­flu­enced which drug pro­grams the com­pa­ny pri­or­i­tized. The com­pa­ny’s chief sci­en­tif­ic of­fi­cer shook his head, look­ing at the oth­er ex­ec­u­tive and then Lo.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.